We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Oct 2017
  • Code : CMI190
  • Pages :130
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

B-Cell Maturation Antigen (BCMA) Targeted Therapy – An innovative therapy for multiple myeloma

Multiple myeloma (MM) refers to a clonal plasma cell malignant neoplasm that is observed in the soft, spongy tissue of the bone marrow. The plasma cells are a crucial part of the immune system, which helps to fight against various types of infections and several other diseases. Multiple myeloma is a type of cancer formed by malignant plasma cells and characterized by low blood counts, renal failure, hypercalcemia, immune suppression, monoclonal gammopathy, and anemia. Moreover, multiple myeloma remains as an incurable disease. According to the American Cancer Society, in 2017, an estimated 30,280 a­­­­­dults (17,490 men and 12,790 women) in the U.S. will be diagnosed with multiple myeloma and 12,590 deaths (6,660 men and 5,930 women) will occur in U.S. in 2017 due to multiple myeloma disease. According to the National Center for Biotechnology Information 2014, multiple myeloma represents 8.2% of all blood cancers in Africa.

B-Cell maturation antigen (BCMA) is a cell surface protein that is expressed on the malignant plasma cells. The expression profiles exhibited by TACI and BAFF-R are comparatively lower than that of the BCMA in multiple myeloma patients. Also, these antigens are hardly detected in the malignant plasma cells thus suggesting BCMA to be a standard choice over the other targeting antigens. The expression of BCMA gradually increases with the progression from normal Monoclonal Gammopathy of Undetermined Significance (MUGA) to smoldering multiple myeloma (SMM) to active multiple myeloma. This unique expression profile is exhibited only by the BCMA cells as they have a very restricted expression pattern and are unexpressed in normal human tissues. BCMA-target therapy has thus gained traction for cancer treatment and will be the choice of treatment especially for multiple myeloma. BCMA possess co-immunoprecipitation property with a master transcription factor (IRF-4) that are mediated for myeloma cell survival. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs).

However, high cost involved in multiple combinational drug as well as maintenance therapy is expected to hinder growth of the BCMA targeted therapies market.

Key players in the market are focused on product development and conducting preclinical and clinical trials to assess the efficacy of these products mainly through the safety profile offered by these therapies.

Fig. 1. B-Cell Maturation Antigen (BCMA) targeted pipeline products

B-Cell Maturation Antigen Market | Coherent Market Insights

To learn more about this report, request a free sample copy

Source: Coherent Market Insights 2017

Increasing number of pipeline products is expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market

Market players are actively investing in research and development of novel multiple myeloma therapies. These therapies include chimeric antigen receptor T cells, antibody-drug conjugate, and Bi-specific antibodies. For instance, GlaxoSmithKline Plc. (GSK2857916) is developing the antibody drug conjugate drug for relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA. The robust pipeline of therapies for the treatment of multiple myeloma is expected to boost growth of the B-cell maturation Antigen targeted therapies market.

Increasing number of recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market

The patients undergoing chemotherapy and radiation therapy are at high risk of recurrence of cancer as they develop resistance to these therapy. At present there are no treatment options for patients with recurrent cancer and hence the BCMA targeted therapies provide breakthrough therapeutic options for the treatment of relapsed or refractory multiple myeloma, where the existing treatment modalities have proved to be clinically inefficient.

Key players operating in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc., Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Frequently Asked Questions

Major players operating in the global B-cell maturation antigen (BCMA) targeted therapies market include Celgene Corporation, GlaxoSmithKline plc., Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Among indication, multiple myeloma segment is expected to hold dominant position in the market.

High cost involved in multiple combinational drug as well as maintenance therapy is one of the major factors that is expected to hamper growth of the market over the forecast period.

Increasing number of pipeline products is one of the major factors that is expected to propel growth of the market over the forecast period.

Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

BCMA-target therapy has gained traction for cancer treatment and will be the choice of treatment especially for multiple myeloma. Increasing prevalence of multiple myeloma is one of the factors influencing the adoption of B-cell maturation antigen (BCMA) targeted therapies globally.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo